BFM
SABS icon

Boothbay Fund Management’s SAB Biotherapeutics SABS Stock Holding History

Boothbay Fund Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.78M Hold
1,481,660
– – 0.08% 308
2026
Q1 		$5.67M Buy
+1,481,660
New +$5.91M 0.07% 285
2021
Q3 		– Sell
-40,000
Closed -$3.98M – 2148
2021
Q2 		$3.98M Buy
+40,000
New +$3.97M 0.13% 176

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boothbay Fund Management's SABS Position: Q2 2026 in Review

Boothbay Fund Management held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 1,481,660 shares worth $5.78M. The position accounts for 0.08% of the portfolio, ranked #308.

Boothbay Fund Management first reported a position in SABS in Q2 2021 and has held it in 3 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Boothbay Fund Management held 1,481,660 shares of SAB Biotherapeutics worth $5.78M as of Q2 2026.
  • Boothbay Fund Management left its SAB Biotherapeutics share count unchanged in Q2 2026.
  • SAB Biotherapeutics made up 0.08% of Boothbay Fund Management's portfolio in Q2 2026, its #308 holding.
  • Boothbay Fund Management first reported a position in SAB Biotherapeutics in Q2 2021 and has held it in 3 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.